GALAPAGOS NV/S ADR (NASDAQ:GLPG) and Gilead Sciences, Inc. (NASDAQ:GILD) were advancing strongly Wednesday following the release of clinical trial data for their pipeline candidate filgotinib.
Galapagos shares were rallying 17.95 percent to $121.18 at the time of publication, while Gilead was up 2.66 percent at $74.15.
What Happened
"The primary endpoint was the proportion of patients achieving an ACR20 response at week 12," the companies said.
Filgotinib was tested as a once-daily regimen in 100mg and 200mg doses.
The study also revealed that the pipeline candidate was generally well-tolerated.
Why It's Important
The fact that filgotinib demonstrated significantly improved clinical responses in the difficult-to-treat population bodes well for the results of the FINCH 1 and FINCH 3 trials, which are evaluating the candidate in other patient populations with rheumatoid arthritis.
What's Next
The companies said detailed findings from the FINCH 2 study will be presented at a future scientific conference.
Filgotinib is being evaluated by Galapagos and Gilead for other inflammatory indications such as psoriatic arthritis (Phase 2 EQUATOR Study), ulcerative colitis (Phase 3 SELECTION Study), ankylosing spondylitis (TORTUGA Study) and Crohn's disease (Phase 3 DIVERSITY Study).
Related Links:
New Class of Migraine Drug Creates Four-Way Pharma Development Race
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
